Contact
searchSearch
HMP Global
Login

Acute Myeloid Leukemia Specialty Channel

Acute Myeloid Leukemia
Specialty Channel
News
Venetoclax and Hypomethylating Agent Treatment Shows Efficacy for R/R Acute Myeloid Leukemia, With Genetic Predictors of Response Identified
02/28/2025
Emily Estrada
Venetoclax plus hypomethylating agents demonstrated efficacy for treating R/R AML, with genetic features, including distinct mutations, predicting response to treatment, according to a retrospective study.
Venetoclax plus hypomethylating agents demonstrated efficacy for treating R/R AML, with genetic features, including distinct mutations, predicting response to treatment, according to a retrospective study.
Venetoclax plus hypomethylating...
02/28/2025
Oncology
News
Autologous Hematopoietic Stem Cell Transplantation as Additional Treatment Option for Secondary Acute Myeloid Leukemia
02/28/2025
Emily Estrada
While allogeneic hematopoietic stem cell transplantation is the standard treatment for secondary AML, autologous hematopoietic stem cell transplantation shows promising outcomes as an additional treatment option, according to a retrospective...
While allogeneic hematopoietic stem cell transplantation is the standard treatment for secondary AML, autologous hematopoietic stem cell transplantation shows promising outcomes as an additional treatment option, according to a retrospective...
While allogeneic hematopoietic...
02/28/2025
Oncology
FDA Approval
FDA Approves Treosulfan With Fludarabine for Patients With AML or MDS Prior to AlloHSCT
02/07/2025
Emily Estrada
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA...
02/07/2025
Oncology
News
Midostaurin Plus CLAG-M Yields Comparable Results to Midostaurin Plus 7+3 Therapy, High Remission Rates Among Patients With FLT3-Mutated AML
01/31/2025
Emily Estrada
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
For patients with AML and FLT3...
01/31/2025
Oncology
News
Venetoclax Plus Hypomethylating Agents Demonstrated Improved Outcomes and Infection Risk Among Older Patients With Acute Myeloid Leukemia
01/31/2025
Emily Estrada
Venetoclax combined with hypomethylating agents for the treatment of acute myeloid leukemia improved infection rates and outcomes among patients, as compared to other chemotherapies, according to a retrospective analysis.
Venetoclax combined with hypomethylating agents for the treatment of acute myeloid leukemia improved infection rates and outcomes among patients, as compared to other chemotherapies, according to a retrospective analysis.
Venetoclax combined with...
01/31/2025
Oncology
News
Relationship Between BCL-2 Expression and Venetoclax Concentration Among Patients With AML
01/24/2025
Emily Estrada
Higher levels of BCL-2 expression at time of diagnosis may be associated with worse outcomes while higher blood concentrations of venetoclax may have an impact on timing of adverse reactions among patients with AML, according to a recent...
Higher levels of BCL-2 expression at time of diagnosis may be associated with worse outcomes while higher blood concentrations of venetoclax may have an impact on timing of adverse reactions among patients with AML, according to a recent...
Higher levels of BCL-2...
01/24/2025
Oncology
News
Pevonedistat and Belinostat Therapy Demonstrates Safety, Modest Activity for Patients With R/R Acute Myeloid Leukemia or High-Risk MDS
01/24/2025
Emily Estrada
According to results from a dose escalation phase 1 study, combination belinostat and pevonedistat therapy for relapsed/refractory acute myeloid leukemia or high-risk MDS demonstrated some activity and limited toxicity.
According to results from a dose escalation phase 1 study, combination belinostat and pevonedistat therapy for relapsed/refractory acute myeloid leukemia or high-risk MDS demonstrated some activity and limited toxicity.
According to results from a dose...
01/24/2025
Oncology
News
Olutasidenib and Azacitidine Show Efficacy and Durability for Treatment of R/R mIDH1 Acute Myeloid Leukemia
01/24/2025
Emily Estrada
Olutasidenib and azacitidine combination therapy for relapsed/refractory acute myeloid leukemia demonstrated durable patient responses and safety.
Olutasidenib and azacitidine combination therapy for relapsed/refractory acute myeloid leukemia demonstrated durable patient responses and safety.
Olutasidenib and azacitidine...
01/24/2025
Oncology
News
FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation
11/17/2024
On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.
On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.
On November 15, 2024, the FDA...
11/17/2024
Oncology
News
Gilteritinib Following AlloHCT Shows No Improvement in Health-Related Quality of Life Among Patients With FLT3-ITD AML
10/31/2024
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy...
10/31/2024
Oncology
Jonathan Canaani, MD
Conference Coverage
Advances in Risk Stratification and Treatment for Patients With AML
10/24/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia &...
10/24/2024
Oncology

News

News
Venetoclax and Hypomethylating Agent Treatment Shows Efficacy for R/R Acute Myeloid Leukemia, With Genetic Predictors of Response Identified
02/28/2025
Emily Estrada
Venetoclax plus hypomethylating agents demonstrated efficacy for treating R/R AML, with genetic features, including distinct mutations, predicting response to treatment, according to a retrospective study.
Venetoclax plus hypomethylating agents demonstrated efficacy for treating R/R AML, with genetic features, including distinct mutations, predicting response to treatment, according to a retrospective study.
Venetoclax plus hypomethylating...
02/28/2025
Oncology
News
Autologous Hematopoietic Stem Cell Transplantation as Additional Treatment Option for Secondary Acute Myeloid Leukemia
02/28/2025
Emily Estrada
While allogeneic hematopoietic stem cell transplantation is the standard treatment for secondary AML, autologous hematopoietic stem cell transplantation shows promising outcomes as an additional treatment option, according to a retrospective...
While allogeneic hematopoietic stem cell transplantation is the standard treatment for secondary AML, autologous hematopoietic stem cell transplantation shows promising outcomes as an additional treatment option, according to a retrospective...
While allogeneic hematopoietic...
02/28/2025
Oncology
FDA Approval
FDA Approves Treosulfan With Fludarabine for Patients With AML or MDS Prior to AlloHSCT
02/07/2025
Emily Estrada
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA...
02/07/2025
Oncology
News
Midostaurin Plus CLAG-M Yields Comparable Results to Midostaurin Plus 7+3 Therapy, High Remission Rates Among Patients With FLT3-Mutated AML
01/31/2025
Emily Estrada
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
For patients with AML and FLT3...
01/31/2025
Oncology
News
Venetoclax Plus Hypomethylating Agents Demonstrated Improved Outcomes and Infection Risk Among Older Patients With Acute Myeloid Leukemia
01/31/2025
Emily Estrada
Venetoclax combined with hypomethylating agents for the treatment of acute myeloid leukemia improved infection rates and outcomes among patients, as compared to other chemotherapies, according to a retrospective analysis.
Venetoclax combined with hypomethylating agents for the treatment of acute myeloid leukemia improved infection rates and outcomes among patients, as compared to other chemotherapies, according to a retrospective analysis.
Venetoclax combined with...
01/31/2025
Oncology
News
Relationship Between BCL-2 Expression and Venetoclax Concentration Among Patients With AML
01/24/2025
Emily Estrada
Higher levels of BCL-2 expression at time of diagnosis may be associated with worse outcomes while higher blood concentrations of venetoclax may have an impact on timing of adverse reactions among patients with AML, according to a recent...
Higher levels of BCL-2 expression at time of diagnosis may be associated with worse outcomes while higher blood concentrations of venetoclax may have an impact on timing of adverse reactions among patients with AML, according to a recent...
Higher levels of BCL-2...
01/24/2025
Oncology
News
Pevonedistat and Belinostat Therapy Demonstrates Safety, Modest Activity for Patients With R/R Acute Myeloid Leukemia or High-Risk MDS
01/24/2025
Emily Estrada
According to results from a dose escalation phase 1 study, combination belinostat and pevonedistat therapy for relapsed/refractory acute myeloid leukemia or high-risk MDS demonstrated some activity and limited toxicity.
According to results from a dose escalation phase 1 study, combination belinostat and pevonedistat therapy for relapsed/refractory acute myeloid leukemia or high-risk MDS demonstrated some activity and limited toxicity.
According to results from a dose...
01/24/2025
Oncology
News
Olutasidenib and Azacitidine Show Efficacy and Durability for Treatment of R/R mIDH1 Acute Myeloid Leukemia
01/24/2025
Emily Estrada
Olutasidenib and azacitidine combination therapy for relapsed/refractory acute myeloid leukemia demonstrated durable patient responses and safety.
Olutasidenib and azacitidine combination therapy for relapsed/refractory acute myeloid leukemia demonstrated durable patient responses and safety.
Olutasidenib and azacitidine...
01/24/2025
Oncology
News
FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation
11/17/2024
On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.
On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.
On November 15, 2024, the FDA...
11/17/2024
Oncology
News
Gilteritinib Following AlloHCT Shows No Improvement in Health-Related Quality of Life Among Patients With FLT3-ITD AML
10/31/2024
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy...
10/31/2024
Oncology

Interactive Features

Quiz
Combination Iadademstat and Azacitidine for Patients With Patients With Newly Diagnosed AML
09/25/2024
True or False: According to results from the phase 2a, dose-finding ALICE study, the frontline combination of iadademstat and azacitidine failed to produce promising responses among patients with newly diagnosed acute myeloid leukemia,...
True or False: According to results from the phase 2a, dose-finding ALICE study, the frontline combination of iadademstat and azacitidine failed to produce promising responses among patients with newly diagnosed acute myeloid leukemia,...
True or False: According to...
09/25/2024
Oncology
Quiz
Treating Acute Myeloid Leukemia With Aspacytarabine
03/05/2024
True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.
True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.
True or False: Aspacytarabine...
03/05/2024
Oncology
Quiz
Fractionated Vs Single-Dose Gemtuzumab Ozogamicin Among Older Patients With AML
02/15/2024
True or False: Fractionated gemtuzumab ozogamicin treatment resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab...
True or False: Fractionated gemtuzumab ozogamicin treatment resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab...
True or False: Fractionated...
02/15/2024
Oncology
Quiz
Humanized Bispecific Antibody Vibecotamab for R/R AML
02/07/2024
True or False: Administering vibecotamab at a dose-optimized schedule demonstrated safety and tolerability among patients with primary or secondary, relapsed/refractory acute myeloid leukemia.
True or False: Administering vibecotamab at a dose-optimized schedule demonstrated safety and tolerability among patients with primary or secondary, relapsed/refractory acute myeloid leukemia.
True or False: Administering...
02/07/2024
Oncology
Quiz
Treating TP53-Mutated AML With Venetoclax Plus HMA Therapy
01/10/2024
True or False: According to findings from a retrospective, multi-center, real-world study presented at the 65th American Society of Hematology (ASH) Annual Meeting, venetoclax plus hypomethylating agent (HMA) therapy yielded improvement in...
True or False: According to findings from a retrospective, multi-center, real-world study presented at the 65th American Society of Hematology (ASH) Annual Meeting, venetoclax plus hypomethylating agent (HMA) therapy yielded improvement in...
True or False: According to...
01/10/2024
Oncology
Quiz
Fludarabine-Based Regimen Vs Standard 7 + 3 Regimen for WT1-Mutated AML
12/09/2023
A fludarabine-based regimen did not improve relapse-free survival following allogeneic stem cell transplantation compared to a traditional idarubicin/cytarabine (7 + 3) regimen for the treatment of patients with WT1-mutated acute myeloid...
A fludarabine-based regimen did not improve relapse-free survival following allogeneic stem cell transplantation compared to a traditional idarubicin/cytarabine (7 + 3) regimen for the treatment of patients with WT1-mutated acute myeloid...
A fludarabine-based regimen did...
12/09/2023
Oncology
Quiz
Sorafenib Maintenence After AlloHSCT For FLT3-ITD-Mutated AML
12/04/2023
True or False: Results from a post-hoc analysis from a phase 3 trial indicated that sorafenib maintenance after allogeneic hematopoietic stem-cell transplantation (alloHSCT) was effective among patients with FLT3 internal tandem duplication...
True or False: Results from a post-hoc analysis from a phase 3 trial indicated that sorafenib maintenance after allogeneic hematopoietic stem-cell transplantation (alloHSCT) was effective among patients with FLT3 internal tandem duplication...
True or False: Results from a...
12/04/2023
Oncology
Quiz
Azacitidine, Venetoclax, and Pevonedistat Combination for Secondary AML, MDS, or CMML
11/09/2023
True or False: The triplet combination of azacitidine, venetoclax, and pevonedistat yielded encouraging responses among patients with newly diagnosed secondary AML, MDS, or CMML.
True or False: The triplet combination of azacitidine, venetoclax, and pevonedistat yielded encouraging responses among patients with newly diagnosed secondary AML, MDS, or CMML.
True or False: The triplet...
11/09/2023
Oncology
Quiz
Treating AML With Gemtuzumab Ozogamicin Plus Intensive Chemotherapy
09/26/2023
True or False: Findings from a phase 3 trial indicate that the addition of anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin to intensive chemotherapy demonstrated promising efficacy among patients with newly diagnosed NPM1-mutated AML.
True or False: Findings from a phase 3 trial indicate that the addition of anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin to intensive chemotherapy demonstrated promising efficacy among patients with newly diagnosed NPM1-mutated AML.
True or False: Findings from a...
09/26/2023
Oncology
Quiz
Treating R/R AML With Venetoclax, Azacitidine, and Homoharringtonine
09/11/2023
According to a phase 2 trial, the combination of venetoclax, azacitidine, and homoharringtonine demonstrated _____ among patients with relapsed/refractory acute myeloid leukemia.
According to a phase 2 trial, the combination of venetoclax, azacitidine, and homoharringtonine demonstrated _____ among patients with relapsed/refractory acute myeloid leukemia.
According to a phase 2 trial,...
09/11/2023
Oncology

Recent Stories

News
Venetoclax and Hypomethylating Agent Treatment Shows Efficacy for R/R Acute Myeloid Leukemia, With Genetic Predictors of Response Identified
02/28/2025
Emily Estrada
Venetoclax plus hypomethylating agents demonstrated efficacy for treating R/R AML, with genetic features, including distinct mutations, predicting response to treatment, according to a retrospective study.
Venetoclax plus hypomethylating agents demonstrated efficacy for treating R/R AML, with genetic features, including distinct mutations, predicting response to treatment, according to a retrospective study.
Venetoclax plus hypomethylating...
02/28/2025
Oncology
News
Autologous Hematopoietic Stem Cell Transplantation as Additional Treatment Option for Secondary Acute Myeloid Leukemia
02/28/2025
Emily Estrada
While allogeneic hematopoietic stem cell transplantation is the standard treatment for secondary AML, autologous hematopoietic stem cell transplantation shows promising outcomes as an additional treatment option, according to a retrospective...
While allogeneic hematopoietic stem cell transplantation is the standard treatment for secondary AML, autologous hematopoietic stem cell transplantation shows promising outcomes as an additional treatment option, according to a retrospective...
While allogeneic hematopoietic...
02/28/2025
Oncology
FDA Approval
FDA Approves Treosulfan With Fludarabine for Patients With AML or MDS Prior to AlloHSCT
02/07/2025
Emily Estrada
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA...
02/07/2025
Oncology
News
Midostaurin Plus CLAG-M Yields Comparable Results to Midostaurin Plus 7+3 Therapy, High Remission Rates Among Patients With FLT3-Mutated AML
01/31/2025
Emily Estrada
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
For patients with AML and FLT3...
01/31/2025
Oncology
News
Venetoclax Plus Hypomethylating Agents Demonstrated Improved Outcomes and Infection Risk Among Older Patients With Acute Myeloid Leukemia
01/31/2025
Emily Estrada
Venetoclax combined with hypomethylating agents for the treatment of acute myeloid leukemia improved infection rates and outcomes among patients, as compared to other chemotherapies, according to a retrospective analysis.
Venetoclax combined with hypomethylating agents for the treatment of acute myeloid leukemia improved infection rates and outcomes among patients, as compared to other chemotherapies, according to a retrospective analysis.
Venetoclax combined with...
01/31/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use